Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Ono-7579. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 20/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ono-7579 SCHEMBL19019676 | 0.94 | NTRK1 (0.88) | NTRK1 | |
| Ono-7579 SCHEMBL19019662 | 0.94 | NTRK1 (0.98) | NTRK1 | |
| Ono-7579 SCHEMBL15989430 | 0.94 | NTRK1 (1.00) | NTRK1 | |
| Ono-7579 SCHEMBL19019664 | 0.93 | NTRK1 (0.98) | NTRK1 | |
| Ono-7579 SCHEMBL19019673 | 0.93 | NTRK1 (0.98) | NTRK1 | |
| SCHEMBL17360594 | 0.88 | NTRK1 (0.88) | NTRK1 | |
| SCHEMBL17360111 | 0.87 | NTRK1 (0.88) | NTRK1 | |
| SCHEMBL17360301 | 0.87 | NTRK1 (1.00) | NTRK1 | |
| SCHEMBL19019670 | 0.86 | NTRK1 (0.85) | NTRK1 | |
| SCHEMBL17360157 | 0.86 | NTRK1 (0.87) | NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10399959-B2 | Acid-addition salt of Trk-inhibiting compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-09-03 | — | — | US | claimed |
| EP-3184519-B1 | ACID-ADDITION SALT OF TRK-INHIBITING COMPOUND | ONO PHARMACEUTICAL CO (JP) | 2019-04-24 | — | — | EP | claimed |
| US-20170240527-A1 | ACID-ADDITION SALT OF Trk-INHIBITING COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-08-24 | — | — | US | claimed |
| EP-3184519-A1 | ACID-ADDITION SALT OF Trk-INHIBITING COMPOUND | ONO Pharmaceutical Co., Ltd. (JP) | 2017-06-28 | — | — | EP | claimed |
| CN-110655502-A | Acid addition salts of Trk inhibiting compounds | 小野药品工业株式会社 | 2020-01-07 | — | — | CN | disclosed |
| US-10399959-B2 | Acid-addition salt of Trk-inhibiting compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-09-03 | — | — | US | disclosed |
| EP-3184519-B1 | ACID-ADDITION SALT OF TRK-INHIBITING COMPOUND | ONO PHARMACEUTICAL CO (JP) | 2019-04-24 | — | — | EP | disclosed |
| US-20170240527-A1 | ACID-ADDITION SALT OF Trk-INHIBITING COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-08-24 | — | — | US | disclosed |
| EP-3184519-A1 | ACID-ADDITION SALT OF Trk-INHIBITING COMPOUND | ONO Pharmaceutical Co., Ltd. (JP) | 2017-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240527-A1 | ACID-ADDITION SALT OF Trk-INHIBITING COMPOUND | NTRK1, NGF, NTRK2 | NTRK1 1/4885 |
| US-10399959-B2 | Acid-addition salt of Trk-inhibiting compound | NTRK1, NGF, NTRK2 | NTRK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.